Chengdu Shuode Pharmaceutical Co.,Ltd.

The main purpose of the study is to evaluate the pharmacokinetic parameters of the test preparation ponatinib tablets (specification: 15 mg, licensee: Chengdu Shuode Pharmaceutical Co., Ltd.) and the reference preparation ponatinib tablets (Iclusig®, specification: 15 mg, licensee: Otsuka Pharmaceutical Co., Ltd.) in healthy participants after a single oral administration in the fasting and fed states, and to evaluate the bioequivalence of the two oral preparations in the fasting and fed states. Secondary study objective: To evaluate the safety of ponatinib tablets (strength: 15 mg) compared with the reference product ponatinib tablets (Iclusig®, strength: 15 mg) in healthy participants.

Main research purpose: According to the relevant provisions of bioequivalence test, Hainan Xiansheng Pharmaceutical Co., Ltd. was selected as the reference preparation of Aguratimod Tablets (trade name: Edexin, specification: 25mg), and the test preparation Aguratimod Tablets (specification: 25mg) produced and provided by Chengdu Shuode Pharmaceutical Co., Ltd. was conducted on the human bioequivalence test of fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation Aguratimod Tablets (specification: 25mg) and the reference preparation Aguratimod Tablets (trade name: Edexin, specification: 25mg) by healthy volunteers.

Main study purpose: According to the relevant provisions of bioequivalence test, the certified Eperisone Hydrochloride Tablets (trade name: Miaona, specification: 50mg) of Eisai (China) Pharmaceutical Co., Ltd. were selected as the reference preparation, and the test preparation Eperisone Hydrochloride Tablets (specification: 50mg) produced and provided by Chengdu Shuode Pharmaceutical Co., Ltd. were subjected to human bioequivalence test on fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation Eperisone Hydrochloride Tablets (specification: 50mg) and the reference preparation Eperisone Hydrochloride Tablets (trade name: Miaona, specification: 50mg) to healthy subjects.